-
1.FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF 有权
Title translation: 结合本达·马斯廷和组蛋白去乙酰化酶抑制剂配方及其用途公开(公告)号:EP2755648A4
公开(公告)日:2015-03-11
申请号:EP11872389
申请日:2011-09-13
Applicant: PHARMACYCLICS INC , SERVIER SAS LAB
Inventor: LOURY DAVID J , BUGGY JOSEPH J , MODY TARAK D , VERNER ERIK J , PURRO NORBERT , BALASUBRAMANIAN SRIRAM , KLOOS IOANA , DEPIL STÉPHANE
IPC: A61K31/343 , A61K31/16 , A61K31/166 , A61P35/00
CPC classification number: A61K31/343 , A61K9/14 , A61K9/28 , A61K9/70 , A61K31/4184 , A61K2300/00
-
2.
公开(公告)号:SG10201607620YA
公开(公告)日:2016-11-29
申请号:SG10201607620Y
申请日:2011-09-13
Applicant: PHARMACYCLICS INC , SERVIER SAS LAB
Inventor: LOURY DAVID J , BUGGY JOSEPH J , MODY TARAK D , VERNER ERIK J , PURRO NORBERT , BALASUBRAMANIAN SRIRAM , KLOOS IOANA , DEPIL STÉPHANE
-
3.
公开(公告)号:AU2011376953A1
公开(公告)日:2014-03-06
申请号:AU2011376953
申请日:2011-09-13
Applicant: PHARMACYCLICS INC , SERVIER SAS LAB
Inventor: LOURY DAVID J , BUGGY JOSEPH J , MODY TARAK D , VERNER ERIK J , PURRO NORBERT , BALASUBRAMANIAN SRIRAM , KLOOS IOANA , DEPIL STEPHANE
IPC: A61K31/343 , A61K31/16 , A61K31/166 , A61P35/00
Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include bendamustine, or a pharmaceutically acceptable salt thereof and an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
-
4.
公开(公告)号:SG2014014419A
公开(公告)日:2014-07-30
申请号:SG2014014419
申请日:2011-09-13
Applicant: PHARMACYCLICS INC , SERVIER SAS LAB
Inventor: LOURY DAVID J , BUGGY JOSEPH J , MODY TARAK D , VERNER ERIK J , PURRO NORBERT , BALASUBRAMANIAN SRIRAM , KLOOS IOANA , DEPIL STÉPHANE
IPC: A61K31/343 , A61K31/16 , A61K31/166 , A61P35/00
-
5.
公开(公告)号:CA2845806A1
公开(公告)日:2013-03-21
申请号:CA2845806
申请日:2011-09-13
Applicant: PHARMACYCLICS INC , SERVIER SAS LAB
Inventor: LOURY DAVID J , BUGGY JOSEPH J , MODY TARAK D , VERNER ERIK J , PURRO NORBERT , BALASUBRAMANIAN SRIRAM , KLOOS IOANA , DEPIL STEPHANE
IPC: A61K31/4184 , A61K31/16 , A61K31/343 , A61K31/47 , A61P35/00
Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include bendamustine, or a pharmaceutically acceptable salt thereof and an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
-
-
-
-